Distribution, clinical correlates and significance of axonal loss and demyelination in chronic inflammatory demyelinating polyneuropathy

European Journal of Neurology

Volumn 18, Issue 2, 2011, Pages 293-299

  Rajabally, Y A ^a   Narasimhan, M ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Axonal loss; Chronic inflammatory demyelinating polyneuropathy; Clinical; Correlations; Demyelination; Distribution; Electrophysiology; Motor; Weakness

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; DEMYELINATION; DISEASE ACTIVITY; ELECTROPHYSIOLOGY; HUMAN; MUSCLE ACTION POTENTIAL; MUSCLE WEAKNESS; NERVE CONDUCTION; NERVE FIBER; PRIORITY JOURNAL; PROGNOSIS;

ACTION POTENTIALS; ADULT; AGED; AGED, 80 AND OVER; AXONS; DEMYELINATING DISEASES; ELECTROMYOGRAPHY; HUMANS; MIDDLE AGED; NEURAL CONDUCTION; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 78751535732     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03138.x     Document Type: Article

References (24)

1. McLeod A, Till S, Sonksen P. Discussion of the clinical trials of the aldose reductase inhibitor, tolrestat. Int Proc J 1991; 4: 17-24.
2. Bril V, Ellison R, Ngo M, et al. Electrophysiological monitoring in clinical trials. Muscle Nerve 1998; 21: 1368-1373.
3. Gilchrist JM, Sachs GM. Electrodiagnostic studies in the management and prognosis of neuromuscular disorders. Muscle Nerve 2004; 29: 165-190.
4. Feasby TE, Brown WF, Gilbert JJ, Hahn AF. The pathological basis of conduction block in human neuropathies. J Neurol Neurosurg Psychiatry 1985; 48: 239-244.
5. Harbo T, Andersen H, Jakobsen J. Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008; 38: 1036-1045.
6. Van Asseldonk JT, Van den Bergh LH, Van den Bergh-Vos RM, Wieneke GH, Wokke JH, Franssen H. Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain 2003; 126: 186-198.
7. Hughes RA, Bouche P, Cornblath DR, et al. European Federation of Neurological societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13: 326-332.
8. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 2006; 77: 973-976.
9. Rhee EK, England JD, Sumner AJ. A computer simulation of conduction block: effects produced by actual block versus interphase cancellation. Ann Neurol 1990; 28: 146-156.
10. Van Asseldonk JT, Van den Bergh LH, Kalmijn S, et al. Axon loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2006; 77: 743-747.
11. Van den Bergh PYK, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2004; 29: 565-574.
12. Vucic S, Black K, Baldassari LE, Siao Tick Chong P, Dawson KT, Cros D. Long-term effects of intravenous immunoglobulin in CIDP. Clin Neurophysiol 2007; 118: 1980-1984.
13. Rajabally YA, Jacob S, Hbahbih M. Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases. J Peripher Nerv Syst 2005; 10: 282-292.
14. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136-141.
15. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119: 1067-1077.
16. Iijima M, Yamamoto M, Hirayama M, et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 2005; 64: 1471-1475.
17. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double- blind, placebo-controlled, crossover study. Neurology 1990; 40: 209-212.
18. Bril V, Katzberg H, Donofrio P, et al. Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 2009; 39: 448-455.
19. Ashworth NL, Zochodne DW, Hahn AF, et al. Impact of plasma exchange on indices of demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2000; 23: 206-210.
20. Van den Bergh PYK, Rutterford CM, Hughes RAC, et al. Pilot randomized controlled trial of methotrexate for chronic inflammatory demyelinating polyneuropathy (RMC Trial): motor nerve conduction studies. J Peripher Nerv Syst 2009; 14: S2.
21. Greene DA, Arezzo JC, Brown MB, and the Zenarestat Study Group. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 1999; 53: 580-591.
22. Laughlin RS, Dyck PJ, Melton RJ 3rd, Leibson RC, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73: 39-45.
23. Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakal J. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a U.K. population. Muscle Nerve 2009; 39: 432-438.
24. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society- First Revision. Eur J Neurol 2010; 17: 356-363.